CV Lattes
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Biomedical scientist with a Masters degree in Genetics from the Federal University of Pernambuco (UFPE) and a Ph.D. in Sciences from the Ribeirão Preto Medical School of the University of São Paulo (FMRP/USP), in the Graduate Program in Clinical Oncology, Stem Cells, and Cell Therapy, with a concentration in Normal and Neoplastic Cell Differentiation. He served as a Post-Doctoral Visiting Fellow at the Hematology Branch of the National Heart, Lung, and Blood Institute (National Institutes of Health, Bethesda, MD, USA; 20212023) and as an assistant researcher at the Clinical and Laboratory Hematology Center of UFPE (20232025). Currently, he is a postdoctoral fellow at the Institute of Biomedical Sciences of the University of São Paulo (ICB/USP), focusing on identifying metabolic vulnerabilities as potential therapeutic targets for acute myeloid leukemia. He has expertise in the molecular pathophysiology of hematological neoplasms and clonal hematologic conditions, working mainly on the identification of diagnostic, prognostic, and therapeutic biomarkers in hematologic malignancies, bone marrow failure syndromes, and sickle cell disease. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Acute myeloid leukemia (AML) is characterized by the clonal expansion of immature myeloid cells, resulting in hematopoietic failure, with symptoms such as anemia and infections. Clinical outcomes are unfavorable, with an estimated overall survival inferior to 25% in five years. AML cells exhibit metabolic reprogramming that promotes dependence on oxidative phosphorylation for ATP producti…
The JAK2V617F mutation is identified in the majority of patients with myeloproliferative neoplasms (MPN), and is considered a diagnostic hallmark for these diseases. Additional mutations in MPL and CALR, which participates of JAK/STAT pathways, are diagnostic markers for 80% of JAK2 negatives patients. Inhibitors of JAK / STAT pathway represent a therapeutic advance in MPN treatment, howe…
| 1 / 1 | Ongoing scholarships in Brazil |
| 1 / 1 | Completed scholarships in Brazil |
| 2 / 2 | All Scholarships |
| Associated processes | |